Tudor Investment Corp’s Immunic IMUX Stock Holding History

Tudor Investment Corp’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-63	Closed	-$689K	–	1412
2014 Q2	$689K	Buy	+63	New	+$442K	0.03%	368

Other funds holding IMUX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SIM

Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tudor Investment Corp's IMUX Position: Q3 2014 in Review

Tudor Investment Corp sold out of Immunic (IMUX) in Q3 2014, closing a stake of 63 shares — an estimated $689K sold.

Tudor Investment Corp first reported a position in IMUX in Q2 2014 and held it in 1 quarter. The position peaked at $689K in Q2 2014. 29 funds tracked by Wall St. Rank hold IMUX as of Q3 2014.

Tudor Investment Corp reported no remaining Immunic position as of Q3 2014 after selling out during the quarter.
Tudor Investment Corp sold 63 Immunic shares in Q3 2014, an estimated $689K.
Tudor Investment Corp first reported a position in Immunic in Q2 2014 and held it in 1 quarter.
Tudor Investment Corp's Immunic position peaked at $689K in Q2 2014.
29 funds tracked by Wall St. Rank held Immunic as of Q3 2014.

Based on Tudor Investment Corp's 13F filing for Q3 2014, filed 14 Nov 2014.